ArticleBreast (Edinburgh, Scotland)2026
Real-world treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States.
Article in Breast (Edinburgh, Scotland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Real-world treatment patterns and outcomes in hormone receptor-positive, HER2-low metastatic breast cancer, 2018-2023: a retrospective, observational, US cohort study.Breast cancer research and treatment · 2026Observational
- Sacituzumab tirumotecan in an advanced HR+/HER2-breast cancer patient with bone marrow metastasis-induced refractory thrombocytopenia: a case report and literature review.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundUp to 60% of metastatic breast cancer (mBC) cases historically classified as human epidermal growth factor receptor 2 (HER2)-negative may be HER2-low, expanding options towards new HER2 targeted treatments. Greater understanding of the current therapeutic journey of this population can help with assessing the potential impact of these novel therapies.
methodsWe conducted a real-world retrospective database study using a United States-based cohort to describe the characteristics, treatment patterns, and outcomes among HER2-low, hormone receptor-positive mBC patients who initiated chemotherapy (index line of therapy [ILOT]) in the metastatic setting either within 6 months of 1 line (L) endocrine therapy (ET) + cyclin-dependent kinase 4/6 inhibitor ("rapid ILOT initiators") or after ≥2L of ET ("index 3L+ group").
resultsOf the 963 patients included, 131 (13.6%) were rapid ILOT initiators and 832 (86.4%) were in the index 3L+ group. Most (80.0%) received single-agent chemotherapy as ILOT, and either a chemotherapy-based regimen (57.0%) or ET ± targeted therapy (26.2%) as a subsequent line (N = 702). Median real-world overall survival (rwOS) from start of ILOT was 18.7 months (95% CI: 17.3, 20.2). Median real-world time to treatment discontinuation or death (rwTTD/D) and real-world time to next treatment or death (rwTTNT/D) were 4.9 (95% CI: 4.6, 5.2) and 5.6 months (95% CI: 5.3, 6.0), respectively. Outcomes were particularly poor among rapid ILOT initiators (median rwOS, rwTTD/D and rwTTNT/D of 15.2, 4.3 and 4.9 months, respectively).
conclusionsPatients receiving chemotherapy following ET had limited benefit from available treatments, highlighting unmet treatment needs in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.